Drug intelligence / Profile preview

BL-001

Development stage: Phase 1
Lead developer: Bloom Science
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

BL-001 is an investigational, first-in-class, oral live biotherapeutic product (LBP) developed by Bloom Science. [1, 2] It consists of two rationally selected human gut microbial strains and is designed to replicate the therapeutic effects of the ketogenic diet without requiring dietary restrictions. [2, 3] The drug targets the gut-brain axis to modulate neurotransmitter levels, aiming to increase gamma-aminobutyric acid (GABA) and restore its balance with glutamate. [2, 4] This mechanism is intended to reduce neuronal hyperexcitability, decrease neuroinflammation, and address oxidative stress. [2] BL-001 is being developed for neurological and metabolic disorders, including drug-resistant epilepsies like Dravet syndrome, amyotrophic lateral sclerosis (ALS), and obesity. [1, 2, 8]

Beyond the preview

Go deeper on BL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-001.

Explore the full profile